News Search Results
Feb 17, 2026, 07:00 ET Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
million people in the U.S. currently have MS.2About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Feb 17, 2026, 06:59 ET Q32 Bio Announces $10.5 Million Registered Direct Offering
WALTHAM, Mass., Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced a $10.5
More news about: Q32 Bio
Feb 17, 2026, 02:25 ET INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.Details of the case: Inovio describes itself as a "biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: THE ROSEN LAW FIRM, P. A.
Feb 16, 2026, 10:46 ET Genotyping Market to Reach $61.6 Billion by 2033 Globally, at 13.8% CAGR: Allied Market Research
Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, and Others), Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics and Others), and End User (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, and Others):
More news about: Allied Market Research
Feb 16, 2026, 10:01 ET Pyrogen Testing Market to Reach $3.6 billion, Globally, by 2033 at 8.4% CAGR: Allied Market Research
that aligns closely with human physiology.The pharmaceutical and biotechnology companies segment to maintain its lead position during the forecast period By end user, the pharmaceutical and biotechnology companies segment accounted for the largest share in 2022, contributing to
More news about: Allied Market Research
Feb 16, 2026, 10:00 ET Lilly to participate in TD Cowen's 46th Annual Health Care Conference
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 16, 2026, 08:00 ET USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 16, 2026, 06:45 ET Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 13, 2026, 17:36 ET QURE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against uniQure N.V.
investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases.
More news about: Robbins LLP
Feb 13, 2026, 16:15 ET Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public
More news about: Nektar Therapeutics
Feb 13, 2026, 16:01 ET AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Feb 13, 2026, 15:00 ET Sphingolipids Market Forecast 2025-2035: Global Value to Reach USD 1,145.6 Million by 2035 at 5.1% CAGR
Bioparticles; Croda International (SphingoCare™); Merck KGaA; CordenPharma International; Lipoid GmbH; Biosynth; LARODAN AB; Santa Cruz Biotechnology, Inc.; Creative Enzymes; and others.Croda's SphingoCare™ range highlights ongoing expansion in cosmetic-grade sphingolipids and ceramide-based
More news about: Future Market Insights
Feb 13, 2026, 10:30 ET Cleanroom Technologies Market worth $ 12.93 billion by 2031 | MarketsandMarkets™
technological, and industry-specific aspects, are collectively driving the growth of cleanroom technologies. Manufacturers of pharmaceuticals, biotechnology, and medical devices are investing in advanced contamination-control systems, such as isolators, modular cleanrooms, and real-time monitoring solutions,
More news about: MarketsandMarkets
Feb 13, 2026, 09:12 ET Soin Neuroscience and Lilac Biosciences Launch Collaboration to Study RNA Signatures in Pain and Neuromodulation
PROVIDENCE, R.I. and DAYTON, Ohio, Feb. 13, 2026 /PRNewswire/ -- Lilac Biosciences, a biotechnology company spun out of the Giuliani RNA Center at Brown University, developing quantitative RNA-based analytical tools, announced a research collaboration
More news about: Soin Neuroscience
Feb 13, 2026, 08:58 ET Intensity Therapeutics Announces Reverse Stock Split
Feb. 13, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
Feb 13, 2026, 08:31 ET Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC
Lunai BioworksLunai Bioworks (NASDAQ: LNAI) is an AI-powered biotech and biodefense company pioneering safe and responsible generative biotechnology. Leveraging advanced machine learning and proprietary phenotypic and neurotoxicity datasets, Lunai is redefining how artificial intelligence can
More news about: Lunai Bioworks Inc.
Feb 13, 2026, 08:31 ET MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
CAMBRIDGE, Mass., Feb. 13, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strong global intellectual property portfolio supporting lead asset
More news about: MetaVia Inc.
Feb 13, 2026, 06:30 ET Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the pricing of a private
More news about: Immunic, Inc.
Feb 13, 2026, 01:04 ET HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer
SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the U.S. Food and Drug Administration
More news about: HanchorBio Inc.
Feb 12, 2026, 16:05 ET Vasa Therapeutics Announces Participation at the 36th Annual Oppenheimer Life Sciences Conference
Calif. and WROCLAW, Poland, Feb. 12, 2026 /PRNewswire/ -- Vasa Therapeutics ("Vasa"), a clinical stage biotechnology company developing novel therapies for cardiovascular and metabolic aging, today announced its participation at the 36th Annual Oppenheimer
More news about: Vasa Therapeutics
Feb 12, 2026, 16:05 ET BioMarin Announces Closing of Private Offering of Senior Notes
securities in any jurisdiction in contravention of applicable law.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Feb 12, 2026, 16:02 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
[Click here for information about joining the class action]Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: Pomerantz LLP
Feb 12, 2026, 14:15 ET Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE) - Contact Kessler Topaz Meltzer & Check, LLP
[email protected]. UNIQURE N.V. CLASS ACTION LAWSUIT COMPLAINT ALLEGEGATIONS uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease ("HD"). uniQure is incorporated in The Netherlands with its
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 12, 2026, 10:45 ET Centivax Initiates Phase 1 First-in-Human Clinical Trial of Universal Flu Vaccine
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 /PRNewswire/ -- Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced that the first participants
More news about: Centivax
Feb 12, 2026, 10:00 ET Yosemite Announces More Than $18 Million Deployed in Grants
example included preclinical research led by Craig Crews at Yale, which contributed to foundational insights behind the formation of Quarry Thera, a biotechnology company developing small molecule drugs that modulate protein interactions in completely novel ways to treat cancer and autoimmune diseases.Collaboration
More news about: Yosemite